A simple question about peanut allergies led Dr. Gideon Lack to a discovery that would change the way the world understands food allergies. What began as curiosity turned into decades of research that reshaped medical advice for millions of parents.
The question that started a revolution
When Dr. Gideon Lack stood before an audience of allergists and pediatricians years ago, he asked what seemed like a straightforward question: how many of them had treated a child with a peanut allergy? In most countries, nearly every hand would go up. Peanut allergies had become one of the most common—and frightening—childhood conditions, affecting about two percent of children in the United States and showing similar numbers in the United Kingdom.
But when Lack presented the identical query at a Tel Aviv conference, merely a handful of physicians indicated affirmative. Among approximately two hundred specialists, scarcely three had managed such an instance. This disparity perplexed him. Jewish children residing in London, possessing genetic profiles akin to those in Israel, exhibited considerably elevated rates of peanut allergy. What, therefore, accounted for this striking divergence?
That puzzling moment set Lack on a journey that would span more than fifteen years and ultimately overturn one of medicine’s most deeply held beliefs about allergy prevention.
Unveiling an unforeseen trend
The answer, as Lack later found, was hiding in plain sight. While spending time in Israel, he noticed something unique about local eating habits. Parents routinely fed their babies “Bamba,” a popular peanut-flavored puff snack, as early as four to six months of age. The product contained significant amounts of peanut protein, and Israeli children consumed it regularly and enthusiastically.
In contrast, parents in the United Kingdom were being instructed to do the precise opposite: to refrain from introducing peanuts or other potential allergens to their babies until they reached an age of several years. The reasoning behind this recommendation appeared logical at the time—if a particular food had the potential to cause allergies, then perhaps postponing its introduction would avert sensitization. However, the remarkably low incidence of peanut allergies observed in Israeli children indicated that this long-held strategy could be entirely mistaken.
Curious, Lack and his team compared the diets of around 10,000 children—half in Israel and half in London—who shared similar ancestry. The results were undeniable: peanut allergies were almost ten times more common among the British group. The only clear difference was when peanuts were introduced into the diet. Israeli babies were consuming the equivalent of ten peanuts a week by their first birthday, while British babies had virtually none.
Although the finding was compelling, it was still an observation. To turn correlation into proof, Lack needed rigorous scientific evidence.
Challenging decades of medical advice
At that juncture, the concept of intentionally introducing peanuts to babies appeared nearly irresponsible. Numerous medical professionals and guardians feared that such a method would trigger allergic responses instead of averting them. Funding bodies were reluctant, and significant ethical issues were prevalent. Despite this, Lack persevered.
In 2008, with support from the U.S. National Institutes of Health, his team launched a large, carefully controlled study called the LEAP trial (Learning Early About Peanut Allergy). The research focused on infants who were already at high risk of developing allergies because of severe eczema or existing egg allergies. The children were randomly divided into two groups: one would avoid peanuts entirely, while the other would be encouraged to eat small amounts of peanut-based foods regularly from as early as four months of age.
Recruiting the 640 participants took two years, and the study followed them for five. The results, when they arrived, were astonishing. Among the children who avoided peanuts, nearly 14% developed peanut allergies by the age of five. In the group that consumed peanuts early, the number dropped to less than 2%. Even among children who had shown early signs of sensitivity, regular peanut consumption cut the risk of developing a full-blown allergy by more than two-thirds.
The information showed a decrease of more than 80% in peanut allergy occurrences for individuals who were exposed to peanuts at an early age—a significant discovery that completely altered previous medical recommendations.
From discovery to transformation
When the results of the LEAP study were released in 2015 in The New England Journal of Medicine, they represented a pivotal moment in the fields of allergy investigation and childhood nutrition. For an extended period, official recommendations had advised postponing contact with allergenic foods. However, the data now unequivocally demonstrated that early exposure, rather than evasion, was the crucial factor in developing tolerance.
The implications were enormous. The American Academy of Pediatrics, which had once advised parents to wait until age three before introducing peanuts, reversed its stance. Updated guidelines issued in 2017 encouraged introducing peanut-containing foods as early as four to six months for most babies.
The ramifications of this alteration were immediate and quantifiable. A 2024 investigation featured in Pediatrics revealed that the prevalence of peanut allergies in American children under three years old had decreased by over 40% since the implementation of the updated recommendations. This signifies that tens of thousands of young individuals are now spared from what was previously a chronic and potentially fatal allergic condition.
The continuous advancement of medical knowledge
For Dr. Lack, the event proved to be both a lesson in humility and a source of validation. He confessed that, similar to numerous other medical professionals, he had previously employed an avoidance tactic with his own offspring. Nevertheless, he also underscored that the circuitous, self-regulating essence of scientific inquiry is what ultimately propels advancement.
“The history of medicine is a series of zigzags,” he explained. “We make recommendations based on the best knowledge we have, and when the evidence changes, so should we.”
That guiding principle still informs his investigations. Currently, Lack is a co-leader of a novel initiative called the SEAL study, which again questions established beliefs. This particular endeavor examines the link between eczema and dietary sensitivities.
For years, doctors believed that food allergies triggered eczema. Now, evidence suggests the relationship works in reverse: babies who develop eczema early may be more likely to later develop food allergies. The SEAL study aims to test whether aggressively treating eczema in the first weeks of life—using moisturizers and mild topical treatments—could prevent allergies from developing in the first place.
The science behind early exposure
The core idea behind this novel investigation is termed the “dual-exposure hypothesis.” This theory suggests that the manner in which the immune system encounters food proteins dictates whether it identifies them as harmless or threatening. When an infant consumes food, exposure via the digestive tract instructs the immune system to accept it. However, exposure through compromised or inflamed skin, a common occurrence with eczema, could yield the opposite outcome, fostering sensitization and allergic responses.
Dr. David Hill, a pediatric allergist at the Children’s Hospital of Philadelphia and a fellow researcher in this field, characterized the immune system as a guardian. He stated, “When infants consume foods early, their immune system recognizes these proteins as benign.” He further added, “However, if those identical proteins enter the body via compromised skin, the immune system might misinterpret them as dangers.”
Lack often explains the idea with a metaphor: “If I knock on your front door and ask to come in, you’ll probably greet me politely. But if I break through a window, you might respond differently.”
If the SEAL investigation validates this hypothesis, it has the potential to revolutionize not only the avoidance of allergies but also global pediatric dermatological and dietary approaches.
Redefining how we think about allergies
The journey from that initial lecture in Tel Aviv to the modern understanding of food allergy prevention demonstrates how scientific discovery can rewrite long-held assumptions. What began as a regional curiosity became one of the most significant shifts in pediatric medicine in recent decades.
Dr. Lack’s work has already changed the lives of countless families. Where once parents were told to avoid peanuts out of fear, they are now encouraged to introduce them early and safely—often under pediatric supervision. The research has also inspired further studies on other allergenic foods, from eggs to tree nuts, suggesting that early introduction could help reduce the global burden of allergies more broadly.
For Lack and his colleagues, the goal has never been merely to publish findings but to create real-world change. As he often reminds his audiences, science advances not by being perfect but by being willing to admit when it’s wrong. The key, he believes, is staying open to evidence, even when it contradicts everything we thought we knew.
From the laughter of Israeli babies eating Bamba to the laboratory trials that followed, the story of peanut allergy prevention is a testament to persistence, humility, and the power of questioning assumptions. It reminds us that in science, as in life, progress rarely moves in a straight line—but every discovery brings us closer to understanding, healing, and prevention.
